KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Cash (2016 - 2025)

Historic Change in Cash for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $136.2 million.

  • Jazz Pharmaceuticals' Change in Cash fell 8420.68% to $136.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$892.1 million, marking a year-over-year decrease of 20109.02%. This contributed to the annual value of $906.6 million for FY2024, which is 4508.86% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Change in Cash stood at $136.2 million, which was down 8420.68% from -$672.1 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Change in Cash's 5-year high stood at $1.0 billion during Q1 2021, with a 5-year trough of -$1.2 billion in Q2 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' median Change in Cash value was $53.4 million (recorded in 2023), while the average stood at $14.1 million.
  • Examining YoY changes over the last 5 years, Jazz Pharmaceuticals' Change in Cash showed a top increase of 151810.83% in 2021 and a maximum decrease of 152771.43% in 2021.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Change in Cash stood at -$80.3 million in 2021, then surged by 152.44% to $42.1 million in 2022, then soared by 305.04% to $170.6 million in 2023, then rose by 14.13% to $194.7 million in 2024, then plummeted by 30.06% to $136.2 million in 2025.
  • Its last three reported values are $136.2 million in Q3 2025, -$672.1 million for Q2 2025, and -$550.9 million during Q1 2025.